A biotech had successfully completed Phase I clinical trials and was rapidly progressing into Phase II. Serious adverse event (SAE) volume was expected to significantly increase and therefore associated workload could not be managed in-house.
Qinecsa established a compliant and robust drug safety framework in line with budget and quality expectations to manage increased case volumes.
